Mehmood Tahir, Taylor Michelle, Winters Jeffrey L
Division of Hospital Internal Medicine, Department of Internal Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Transfuse Solutions, Inc, 413 9th Avenue Northwest, Byron, MN 55920, USA.
Hematol Oncol Clin North Am. 2016 Jun;30(3):679-94. doi: 10.1016/j.hoc.2016.01.009. Epub 2016 Mar 30.
Thrombotic microangiopathies are a heterogeneous group of inherited and acquired disorders sharing a common clinical presentation of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. These disorders have been treated with plasma exchange (TPE) based on randomized controlled trials, which found this therapy to be effective in thrombotic thrombocytopenic purpura (TTP). For the remaining disorders, low- to very low-quality evidence exists for the use of TPE. When TPE is applied, the treatment regimen used for TTP is usually applied. There is a need for further evaluation of the role of TPE in the treatment of thrombotic microangiopathies other than TTP.
血栓性微血管病是一组异质性的遗传性和获得性疾病,具有微血管病性溶血性贫血、血小板减少和器官损伤的共同临床表现。基于随机对照试验,这些疾病已采用血浆置换(TPE)进行治疗,该试验发现这种疗法对血栓性血小板减少性紫癜(TTP)有效。对于其余疾病,使用TPE的证据质量低至极低。当应用TPE时,通常采用用于TTP的治疗方案。有必要进一步评估TPE在治疗除TTP之外的血栓性微血管病中的作用。